Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

A novel polymorphism in A… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.

Artikel i vetenskaplig tidskrift
Författare Jackson K Mukonzo
Daniel Röshammar
Paul Waako
Maria Andersson
Takashi Fukasawa
Lili Milani
Jan Olof Svensson
Jasper Ogwal-Okeng
Lars L Gustafsson
Eleni Aklillu
Publicerad i British journal of clinical pharmacology
Volym 68
Nummer/häfte 5
Sidor 690-9
ISSN 1365-2125
Publiceringsår 2009
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi
Sidor 690-9
Språk en
Länkar dx.doi.org/10.1111/j.1365-2125.2009...
Ämnesord Adult, African Continental Ancestry Group, genetics, Anti-HIV Agents, pharmacokinetics, Benzoxazines, pharmacokinetics, Dose-Response Relationship, Drug, Female, Humans, Male, Models, Biological, Models, Genetic, Polymorphism, Genetic, genetics, Sex Factors, Uganda, Young Adult
Ämneskategorier Biofarmaci, Farmakologi och toxikologi

Sammanfattning

AIMS: Efavirenz exhibits pharmacokinetic variability causing varied clinical response. The aim was to develop an integrated population pharmacokinetic/pharmacogenetic model and investigate the impact of genetic variations, sex, demographic and biochemical variables on single-dose efavirenz pharmacokinetics among Ugandan subjects, using NONMEM. METHODS: Efavirenz plasma concentrations (n = 402) from 121 healthy subjects were quantified by high-performance liquid chromatography. Subjects were genotyped for 30 single nucleotide polymorphisms (SNPs), of which six were novel SNPs in CYP2B6, CYP3A5 and ABCB1. The efavirenz pharmacokinetics was described by a two-compartment model with zero- followed by first-order absorption. RESULTS: Apparent oral clearance (95% confidence interval) was 4 l h l(-1) (3.5, 4.5) in extensive metabolizers. In the final model, incorporating multiple covariates, statistical significance was found only for CYP2B6*6 and CYP2B6*11 on apparent oral clearance as well as ABCB1 (rs3842) on the relative bioavailability. Subjects homozygous for CYP2B6*6 (G516T, A785G) and *11 displayed 21 and 20% lower apparent oral clearance, respectively. Efavirenz relative bioavailability was 26% higher in subjects homozygous for ABCB1 (rs3842). The apparent peripheral volume of distribution was twofold higher in women compared with men. CONCLUSIONS: The model identified the four factors CYP2B6*6, CYP2B6*11, a novel variant allele in ABCB1 (rs3842) and sex as major predictors of efavirenz plasma exposure in a healthy Ugandan population after single-dose administration. Use of mixed-effects modelling allowed the analysis and integration of multiple pharmacogenetic and demographic covariates in a pharmacokinetic population model.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?